Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

5)

n/a

n/a

(69.5)

(69.5)Duodopa

--

129

129

n/a

16.6

19.4

16.6

19.4Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.
n/a = not applicable  AbbVie Inc.
Consolidated Statements of Earnings
Quarter and Nine Months Ended September 30, 2013 and 2012
(Unaudited) (In millions, except per share data)Third Quarter Ended September 30Nine Months Ended
September 302013201220132012Net sales

$4,658$4,508$13,679$13,174Cost of products sold

1,0921,0143,2993,243Selling, general and administrative

1,2611,0853,9043,578Research and development

7148132,0572,097Acquired in-process research and development

220--290260Total operating cost and expenses

3,2872,9129,5509,178Operating earnings

1,3711,5964,1293,996Interest (income) expense, net

69(1)210(4)Net foreign exchange (gain) loss

1164027Other (income) expense, net

5(13)(14)(39)Earnings before income tax

1,2861,6043,8934,012Income tax expense

32219893277Net earnings

$964$1,585$3,000$3,735Diluted earnings per share

$0.60$1.01$1.86$2.37Average diluted shares outstanding1,6051,5771,6021,577Note: On Jan. 1, 2013, Abbott Laboratories distributed 1,577 million shares of AbbVie common stock to Abbott's shareholders in connection with the separation of AbbVie from Abbott. The computation of diluted earnings per share for the quarter and nine months ended Sept. 30, 2012 was calculated using the shares distributed on Jan. 1, 2013. AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended September 30, 2013
(Unaudited) (In millions, except per share data)1. Specified items impacted results as follows:3Q13Earnings

DilutedPre-tax

After-tax

EPSAs
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. AbbVie Named a Science Top Employer
2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. AbbVie Declares Quarterly Dividend
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... Celladon Corporation ("Celladon" or the "Company") (NasdaqGM: CLDN -News).  ... or his investor relations coordinator Eitan Kimelman ... The investigation concerns whether Celladon and certain of its ... of the Securities Exchange Act of 1934.  ...
(Date:4/27/2015)... , April 27, 2015 Kalorama Information ... medical records (EMR) to grow well past the ... providers, according to a recent report.  The healthcare ... sales and continued efficiency improvements will grow the ... the next five years.  The market for EMR ...
(Date:4/27/2015)... BRH Medical, Ltd., today announced that it ... (510k) with the US Food and Drug Administration (FDA) ... feedback from the FDA during the next quarter and ... pre-market clearance. Additional pre-market regulatory filings are anticipated during ... BRH Medical, commented, "We are thrilled to have reached ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Kalorama: EMR Market Expected To Grow Beyond Incentives 2Kalorama: EMR Market Expected To Grow Beyond Incentives 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2
... WASHINGTON, Nov. 2 The owner and operator of ... guilty to defrauding the Medicare program, announced Assistant Attorney ... Attorney Tim Johnson of the Southern District of Texas ... of Health & Human Services (HHS). , Noel Wayne ...
... , BOSTON, Nov. 2 Schering-Plough Corporation (NYSE: ... ongoing Phase IIa study of narlaprevir (SCH 900518), its ... treatment-naive patients with chronic hepatitis C virus (HCV) genotype ... in which patients received a 4-week lead-in of PEGINTRON(R) ...
Cached Medicine Technology:Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8
(Date:4/27/2015)... (PRWEB) April 27, 2015 Array ... exchange technology, has announced that Lance Hood, senior director ... the fourth annual Direct-to-Consumer Health Care Marketing Summit ... by David Smith, Partner and Director of Payer Services, ... health care consumerism – through a retail/e-commerce perspective – ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Beckman Coulter ... Next-Gen sequencing to study the evolution of neural circuitry ... which will review the mechanisms by which analogous forms ... (LR) body flexions, evolved independently in certain sea slug ... be broadcast live April 30, 2015 at 8:00am PT. ...
(Date:4/27/2015)... The Doctors on Liens mission ... personal injury attorneys with the best doctors working on a ... growth throughout their history and that trend continues with the ... his team in the Tujunga / Sunland area. ... therapist, patients can find comprehensive care and detailed documentation of ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
(Date:4/27/2015)... OH (PRWEB) April 27, 2015 Douglas ... to help his clients feel secure, but also helps secure ... to 7 p.m., Douglas will be manning a booth at ... Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... worthy event that will feature hundreds of adoptable pets from ...
Breaking Medicine News(10 mins):Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2
... of these infant medicines, not product safety, is ... the voluntary withdrawal,- This withdrawal does not affect cough and cold medicines for children ... ... for infants and,children will occur at the October 18 and 19 FDA advisory committee ...
... Oct. 11 Businesses can no longer afford ... spend more than,75 billion dollars on obesity-attributable health ... are lost to obesity-related illness each,year(2). Other costs ... and high turnover rates. Today, business leaders, ...
... * concentrated Tylenol(R) Infants, Drops Plus Cold and ... * PediaCare(R) Infant Drops ... division of McNeil-PPC, Inc., announced today that the,company is voluntarily withdrawing ... directed, these medicines are generally,recognized as safe and effective. While most ...
... and Multimedia Healthcare Communication, PARIS, October 11 ... today two key acquisitions designed to reinforce its ... acquisitions,aim at strengthening Publicis Groupe,s leadership in both ... (Salerno), a highly innovative agency, specialized in,digital communications ...
... Has,a Story," a grassroots and integrated media project celebrating babies ... to survive and thrive --,has been launched by the March ... over the country tell,a special story about the baby they ... March of Dimes. "Families can also express their,hopes and dreams ...
... SACRAMENTO, Calif., Oct. 10 The governor ... (CSU) retirees to,participate in a self-funded comprehensive vision ... the Legislature and governor have recognized,the need to ... said,Barbara LaPlante, President of CSEA Retirees, Inc. "When ...
Cached Medicine News:Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 2Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 2Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 4Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 2Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 4Health News:'Every Baby Has a Story' Campaign Tours the Nation for March of Dimes 2Health News:Governor Signs Bill Providing Vision Care Program for State University Retirees 2
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... aspiration holes and additional electrode tip ... precise dissection with decreased risk of ... ,Flexible design options allow the ... and multiple tip designs. Optimize specific ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: